Literature DB >> 20643896

The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner.

Hermann Bultmann1, Gary Girdaukas, Glen S Kwon, Curtis R Brandt.   

Abstract

The linear cationic amphiphilic EB peptide, derived from the FGF4 signal sequence, was previously shown to be virucidal and to block herpes simplex type I (HSV-1) entry (H. Bultmann, J. S. Busse, and C. R. Brandt, J. Virol. 75:2634-2645, 2001). Here we show that cells treated with EB (RRKKAAVALLPAVLLALLAP) for less than 5 min are also protected from infection with HSV-1. Though protection was lost over a period of 5 to 8 h, it was reinduced as rapidly as during the initial treatment. Below a 20 μM concentration of EB, cells gained protection in a serum-dependent manner, requiring bovine serum albumin (BSA) as a cofactor. Above 40 μM, EB coprecipitated with BSA under hypotonic conditions. Coprecipitates retained antiviral activity and released active peptide. NaCl (≥0.3 M) blocked coprecipitation without interfering with antiviral activity. As shown for β-galactosidase, EB below 20 μM acted as an enzyme inhibitor, whereas above 40 to 100 μM EB, β-galactosidase was precipitated as was BSA or other unrelated proteins. Pyrene fluorescence spectroscopy revealed that in the course of protein aggregation, EB acted like a cationic surfactant and self associated in a process resembling micelle formation. Both antiviral activity and protein aggregation did not depend on stereospecific EB interactions but depended strongly on the sequence of the peptide's hydrophobic tail. EB resembles natural antimicrobial peptides, such as melittin, but when acting in a nonspecific detergent-like manner, it primarily seems to target proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643896      PMCID: PMC2944556          DOI: 10.1128/AAC.00495-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Mode of action of linear amphipathic alpha-helical antimicrobial peptides.

Authors:  Z Oren; Y Shai
Journal:  Biopolymers       Date:  1998       Impact factor: 2.505

Review 2.  The nervous system and innate immunity: the neuropeptide connection.

Authors:  Kim A Brogden; Janet M Guthmiller; Michel Salzet; Michael Zasloff
Journal:  Nat Immunol       Date:  2005-06       Impact factor: 25.606

Review 3.  The co-evolution of host cationic antimicrobial peptides and microbial resistance.

Authors:  Andreas Peschel; Hans-Georg Sahl
Journal:  Nat Rev Microbiol       Date:  2006-06-12       Impact factor: 60.633

Review 4.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.

Authors:  Robert E W Hancock; Hans-Georg Sahl
Journal:  Nat Biotechnol       Date:  2006-12       Impact factor: 54.908

Review 5.  Detergent-like actions of linear amphipathic cationic antimicrobial peptides.

Authors:  Burkhard Bechinger; Karl Lohner
Journal:  Biochim Biophys Acta       Date:  2006-07-13

6.  Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore.

Authors:  K Matsuzaki; O Murase; N Fujii; K Miyajima
Journal:  Biochemistry       Date:  1995-05-16       Impact factor: 3.162

7.  Analysis of albumin-associated peptides and proteins from ovarian cancer patients.

Authors:  Mark S Lowenthal; Arpita I Mehta; Kristina Frogale; Russell W Bandle; Robyn P Araujo; Brian L Hood; Timothy D Veenstra; Thomas P Conrads; Paul Goldsmith; David Fishman; Emanuel F Petricoin; Lance A Liotta
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

8.  Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.

Authors:  Jeremy C Jones; Elizabeth A Turpin; Hermann Bultmann; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

9.  Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes.

Authors:  R A Cruciani; J L Barker; S R Durell; G Raghunathan; H R Guy; M Zasloff; E F Stanley
Journal:  Eur J Pharmacol       Date:  1992-08-03       Impact factor: 4.432

10.  Immobilization of saccharides and peptides on 96-well microtiter plates coated with methyl vinyl ether-maleic anhydride copolymer.

Authors:  A Satoh; K Kojima; T Koyama; H Ogawa; I Matsumoto
Journal:  Anal Biochem       Date:  1998-06-15       Impact factor: 3.365

View more
  7 in total

1.  Identification of the minimal active sequence of an anti-influenza virus peptide.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

2.  The Entry Blocker Peptide Produced in Chlamydomonas reinhardtii Inhibits Influenza Viral Replication in vitro.

Authors:  Karen Lizbeth Reyes-Barrera; Ruth Elena Soria-Guerra; Rogelio López-Martínez; Leonor Huerta; Nohemí Salinas-Jazmín; Carlos Cabello-Gutiérrez; Ángel Gabriel Alpuche-Solís
Journal:  Front Plant Sci       Date:  2021-05-12       Impact factor: 5.753

3.  Antiviral activity of the EB peptide against zoonotic poxviruses.

Authors:  Sharon E Altmann; Curtis R Brandt; Peter B Jahrling; Joseph E Blaney
Journal:  Virol J       Date:  2012-01-06       Impact factor: 4.099

4.  Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.

Authors:  Wei Hong; Runhong Zhang; Zhiyong Di; Yawen He; Zhenhuan Zhao; Jun Hu; Yingliang Wu; Wenxin Li; Zhijian Cao
Journal:  Biomaterials       Date:  2013-02-13       Impact factor: 12.479

Review 5.  Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity.

Authors:  Hussain Badani; Robert F Garry; William C Wimley
Journal:  Biochim Biophys Acta       Date:  2014-04-26

Review 6.  Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex Viruses in vitro.

Authors:  Francisco J Ibáñez; Mónica A Farías; Maria P Gonzalez-Troncoso; Nicolás Corrales; Luisa F Duarte; Angello Retamal-Díaz; Pablo A González
Journal:  Front Microbiol       Date:  2018-10-11       Impact factor: 5.640

Review 7.  Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections.

Authors:  Raghuram Koganti; Tejabhiram Yadavalli; Deepak Shukla
Journal:  Microorganisms       Date:  2019-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.